Novo Nordisk Pharmatech brings recombinant insulin expertise to CLD Asia


Novo Nordisk Pharmatech brings recombinant insulin expertise to CLD Asia


Novo Nordisk Logo

Press Release | Novo Nordisk Pharmatech A/S

MAY 08, 2017

Koege, Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality ingredients for the biopharmaceutical, pharmaceutical and personal care industries, will be exhibiting its recombinant insulin for innovative biologics at the annual Cell Line Development Asia expo in Shanghai.

Novo Nordisk Pharmatech’s stand at Booth 12 at the Hilton Shanghai Hongqiao will focus on the influential role of recombinant insulin in innovative biologics. Visitors will also have the chance to test their knowledge and win an Amazon Kindle.

Serum-free growth media

Novo Nordisk Pharmatech is the leading worldwide supplier of recombinant insulin, which is a key component in serum free growth media for mammalian cells. The company’s insulin is manufactured to cGMP standards and is approved by FDA, EMA and other world regulatory bodies.

“We are able to guarantee global regulatory compliance with extensive supporting documentation, consistent high quality and continuous availability on a secure global supply chain with high levels of service and support,” said Novo Nordisk Pharmatech Insulin Sales Manager Magnus Franzmann.

Consistent purity

“We deliver a proven record of product purity and consistency and can even tailor product specifications to support emerging therapies,” Mr. Franzmann added.

“For example, we can Increase viable CHO cell density in commercial available cell culture media by supplementing with non-animal insulin,” he explained.

Production benefits

CHO (Chinese hamster ovary) cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media to animal serum-free and latterly to chemically defined media.

Novo Nordisk Pharmatech has collaborated with UAB to show that adding animal-free insulin to leading commercially available off-the-shelf chemically defined media can result in significant increases in viable cell density. Additionally, recombinant insulin has been proven to aid in production of difficult to express proteins.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, haemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2015, Novo Nordisk reported world sales totalling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About Cell Line Development Asia 2017

The Cell Line Development & Engineering Asia conference was founded in 2011 to provide a platform for discussion on accelerating cell line products time to market, increasing efficiency, efficacy and improving quality in the cell line development process.

The 6th Annual Cell Line Development Asia summit is a four-day event opening May 15 at the Hilton Shanghai Hongqiao as part of Biopharma Development & Production week, co- located with Biosimilars and Biomanufacturing conferences.

Key topics will Be Covered Include: early cell line development, gene-editing tools in cell line engineering, antibody therapy, assay development and screening.

The event is organized by IBC Life Sciences with more information at: http://www.celllineasia.com

Media Contact

Magnus Franzmann, Insulin Sales Manager, Novo Nordisk Pharmatech A/S

45 2429 41054
Email: mgfn@novonordiskpharmatech.com

Resources

Click on Novo Nordisk Pharmatech at CLD Asia conference in Shanghai for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
Click on Recombinant human insulin for scientific information.


Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebenhavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483
Website: http://novonordiskpharmatech.com/


Comments are closed.